---
title: "TIGIT在免疫肿瘤学领域的教训"
date: 2026-03-01T10:30:40Z
draft: ["false"]
tags: [
  "fetched",
  "小药说药"
]
categories: ["Acdemic"]
---
TIGIT在免疫肿瘤学领域的教训 by 小药说药
------
<div><section><section><section powered-by="xmyeditor.com"><section><section><section deep="9"><section><section><section><section><section><span><strong><span><span leaf="">-</span></span></strong></span><span><strong><span><span leaf="">01</span></span></strong></span><span><strong><span><span leaf="">-</span></span></strong></span></section></section></section></section></section><section><p><strong><strong data-brushtype="text" hm_fix="340:375"><b><strong><span leaf="">引言</span></strong></b></strong></strong></p><p><span leaf="">2020年，免疫肿瘤学领域正处于一个转折点。首批PD-1抑制剂证明了免疫检查点疗法对部分癌症患者的变革性潜力，但下一代药物和联合疗法的临床试验却屡屡受挫。随着COVID-19成为药物研发的中心舞台，癌症免疫疗法似乎将迎来一段平静期。然而，当年6月，基因泰克（罗氏子公司）在虚拟ASCO会议上公布了其领先的抗TIGIT抗体tiragolumab的II期结果，暗示在初治肺癌患者中具有令人印象深刻的总体生存获益。这一结果引发了该领域对TIGIT的狂热追逐。</span></p><p><span leaf="">据估计，迄今已有22家公司在220项临床试验中测试了30种抗TIGIT候选药物，招募了49，000名患者，总成本估计在31至36亿美元之间。然而，TIGIT抑制剂距离患者仍很遥远。去年，基因泰克tiragolumab在肺癌中的III期试验失败，促使该公司缩减了其广泛的TIGIT研发计划，该计划曾涵盖肺癌、肝癌、食管癌等多个癌种。许多其他公司也已搁置了其抗TIGIT抗体项目。</span></p><p><span leaf=""><br></span><span lang="EN-US"><p></p></span></p></section><section data-role="list" mp-original-font-size="17" mp-original-line-height="27"><p><span><strong><span><span leaf="">-</span></span></strong></span><span><strong><span><span leaf="">02</span></span></strong></span><span><strong><span><span leaf="">-</span></span></strong></span></p><section><h4><strong><span leaf=""><span textstyle="">一、</span></span><b data-pm-slice="0 0 []"><b data-pm-slice="0 0 []"><span leaf="" data-pm-slice="0 0 []">从希望到挫折：临床试验的“过山车”之旅</span></b></b><span><span lang="EN-US"><p></p></span></span></strong></h4><p><span leaf="">TIGIT的发现早于免疫肿瘤学革命。研究人员最初希望通过激活TIGIT来治疗自身免疫性疾病，但后来发现，在临床前小鼠模型中，阻断TIGIT与PD-L1联合可显著缩小结直肠癌和乳腺癌肿瘤。这促使基因泰克推进其tiragolumab的临床开发。</span></p><p><span leaf="">关键的II期CITYSCAPE试验结果在2020年点燃了希望。该试验显示，在PD-L1高表达的NSCLC患者亚组中，tiragolumab联合atezolizumab（抗PD-L1）的客观缓解率达到69%，中位总生存期超过30个月，而atezolizumab单药组为12.8个月。这一结果被广泛解读为TIGIT潜力的有力证明，并促使基因泰克启动了多项III期试验。</span></p><p><span leaf="">然而，随后的III期SKYSCRAPER-01试验未能重现这一成功。尽管tiragolumab联合atezolizumab在数值上改善了中位无进展生存期和总生存期，但这些改善在统计学上并不显著。类似地，在其他癌种（如小细胞肺癌、宫颈癌）的试验中，也未能显示出明确的抗癌疗效。默克等公司的其他抗TIGIT抗体项目也遭遇了挫折。</span></p></section><p><span leaf=""><br></span></p></section><p><span><strong><span><span leaf="">-</span></span></strong></span><span><strong><span><span leaf="">03</span></span></strong></span><span><strong><span><span leaf="">- </span></span><span leaf="" data-pm-slice="0 0 []"><br></span></strong></span></p><h4><strong><span leaf="" data-pm-slice="0 0 []"><span textstyle="">二、</span></span><b data-pm-slice="0 0 []"><span leaf=""><span textstyle="">生物学反思：为何TIGIT疗法未能成功？</span></span></b></strong><span lang="EN-US"><p></p></span></h4><p><span leaf="">业内专家对失败原因提出了多种生物学假设。一种观点认为，PD-1和TIGIT信号通路存在重叠。PD-1受体招募的SHP2磷酸酶会同时关闭共刺激受体CD28和TIGIT的互补共刺激受体CD226。因此，阻断PD-1信号可能已经部分释放了TIGIT-CD226的刹车，使得额外添加抗TIGIT抗体带来的益处有限。</span></p><p><span leaf="">另一种观点指出，TIGIT与CD226的表达存在负相关关系。当T细胞上TIGIT表达升高时，CD226水平会下降。如果CD226水平过低，解除这种刹车可能不会带来太大益处。此外，临床前小鼠模型与人类疾病之间的差异也被认为是导致转化失败的一个重要因素。</span></p></section><p><span leaf=""><br></span></p></section><section><section><section data-pm-slice='5 6 ["para",{"tagName":"section","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{"powered-by":"xmyeditor.com"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{"deep":"9"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{"style":"margin-top: 16px;margin-bottom: 10px;max-width: 100%;max-inline-size: 100%;cursor: text;text-align: center;color: rgb(0, 0, 0);line-height: 1.5em;font-family: 微软雅黑, \"Microsoft YaHei\", sans-serif;text-size-adjust: inherit;outline: none 0px !important;box-sizing: border-box !important;overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><h4><span leaf="" data-pm-slice="0 0 []">-</span><span><strong><span><span leaf="">04</span></span></strong></span><span><strong><span><span leaf="">-</span></span></strong></span></h4><section><h4><strong><strong><span leaf="">三、</span><span leaf="">未来探索：Fc沉默与双特异性抗体</span></strong></strong></h4></section></section></section></section></section><p><strong><span leaf=""><span textstyle="">尽管遭遇挫折，探索并未完全停止，焦点转向了Fc沉默的候选药物。基因泰克的tiragolumab等大多数已中止的抗TIGIT抗体具有活性的Fc结构域，这会消耗表达TIGIT的T效应细胞和调节性T细胞，可能导致免疫介导的副作用增加。吉利德及其合作伙伴Arcus正在推进其Fc沉默的抗TIGIT抗体domvanalimab。阿斯利康和Compugen则押注于一种Fc沉默的TIGIT × PD1双特异性抗体rilvegostomig。这种双特异性方法可能通过协同结合和改善组织暴露提供优势。</span></span></strong></p></section></section></section><section><section><section powered-by="xmyeditor.com"><section><section><section data-pm-slice='5 6 ["para",{"tagName":"section","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{"powered-by":"xmyeditor.com"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{"deep":"9"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{"style":"margin-top: 16px;margin-bottom: 10px;max-width: 100%;max-inline-size: 100%;cursor: text;text-align: center;color: rgb(0, 0, 0);line-height: 1.5em;font-family: 微软雅黑, \"Microsoft YaHei\", sans-serif;text-size-adjust: inherit;outline: none 0px !important;box-sizing: border-box !important;overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><h4><span leaf="" data-pm-slice="0 0 []">-</span><span><strong><span><span leaf="">05</span></span></strong></span><span><strong><span><span leaf="">-</span></span></strong></span></h4><section><h4><strong><strong><span leaf=""><span textstyle="">四、行业教训：从“羊群效应”到理性开发</span></span></strong></strong></h4></section></section></section></section></section></section><span lang="EN-US"><p></p></span></section><section><span leaf=""><span textstyle="">TIGIT的故事为整个行业提供了深刻教训。它再次凸显了“羊群效应”的风险，即当众多公司追逐同一个热门靶点时，可能导致大量资金和临床资源的浪费。这也提醒我们，需要对临床前数据的解读保持谨慎，并开发更能反映人类疾病复杂性的模型。此外，在快速发展的新兴领域中，最好的靶点通常很快会脱颖而出，而后续靶点的验证往往更具挑战性。</span></span></section><p><span leaf=""><span textstyle="">目前，阿斯利康和Compugen正在支持一个已不再受青睐的靶点，他们相信其双特异性方法可能带来不同。无论最终结果如何，TIGIT的历程都强调了冷静、理性药物开发的重要性，以及避免盲目跟风、基于坚实生物学和差异化策略进行创新的必要性。</span></span><b><span lang="EN-US"><p></p></span></b></p><section><span leaf=""><br></span></section><section><span><span leaf="">参考资料：</span></span></section><section><span><span leaf="">TIGIT's immuno-oncology teachings. Nat Rev Drug Discov. 2026 Feb 16. </span></span></section><section><span><span><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"style":"margin-top: 5px;margin-bottom: 5px;text-indent: 0em;white-space: normal;max-width: 100%;min-height: 1em;font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);text-align: left;line-height: normal;box-sizing: border-box !important;overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"span","attributes":{"style":"max-width: 100%;text-indent: 2em;color: rgb(123, 127, 131);font-size: 12px;box-sizing: border-box !important;overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><br></span></span></span><section><section data-color="rgb(63," data-role="paragraph"><p><strong></strong></p><section nodeleaf=""><iframe data-src="https://mp.weixin.qq.com/mp/readtemplate?t=pages/video_player_tmpl&amp;action=mpvideo&amp;auto=0&amp;vid=wxv_4347677401040551939" data-mpvid="wxv_4347677401040551939" data-vidtype="2" data-cover="http%3A%2F%2Fmmbiz.qpic.cn%2Fsz_mmbiz_jpg%2FibZVzbA7glfFuMz7eras36lmkhR9y5BBJXTFvXK461xfyEnthz4ibjPmIw2CpqaZfB1r3WQFEpmRJjdWe8ms3KNQ%2F0%3Fwx_fmt%3Djpeg" data-ratio="1.775" data-w="1278"></iframe></section><p><span leaf=""><br></span></p><p><strong><strong><span><span leaf="">公众号已建立</span><strong><span leaf="">“小药说药专业交流群”</span></strong><span leaf="">微信行业交流群以及读者交流群，扫描下方小编二维码加入</span></span><span><span leaf="">，入行业群请主动告知姓名、工作单位和职务。</span></span></strong></strong></p><p><strong><span leaf=""><br></span></strong></p><section nodeleaf=""><img data-aistatus="1" data-fileid="100009929" data-imgfileid="100026821" data-ratio="0.5849765258215962" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/ibZVzbA7glfGribFrbsykFDSFr2E487tJfSia6BnSicJTYp0abwo8v6PCxpWcg90ibYkYicpJquzOYlt5rTTD8fdlzwg/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" data-type="png" data-w="1065" src="https://mmbiz.qpic.cn/mmbiz_png/ibZVzbA7glfGribFrbsykFDSFr2E487tJfSia6BnSicJTYp0abwo8v6PCxpWcg90ibYkYicpJquzOYlt5rTTD8fdlzwg/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp"></section></section></section></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/cLDfgGtv6veVlvbZK-TSww",target="_blank" rel="noopener noreferrer">原文链接</a>
